GEN Exclusives

More »

GEN News Highlights

More »
Jul 12, 2012

Eppendorf, Vela Develop Nucleic Acid Extraction Platform

  • Eppendorf and Singapore-based Vela Diagnostics (VelaDx) have teamed up to develop an in vitro diagnostic RNA/DNA extraction platform that combines Eppendorf’s pipetting and liquid handling technology with VelaDx’s IVD technologies and workflow expertise. The resulting Sentosa SX platform is based on Eppendorf’s epMotion automated pipetting system, customized using Vela’s diagnostic workflow and features. The platform is capable of setting up and simultaneously carrying out four different tests per run. Vela says the Sentosa workflow systems and test kits will be launched in certain Asian and European markets before the end of 2012, while regulatory submissions are being filed in the U.S.

    “Our collaboration merges an already robust epMotion with revolutionary system enhancements,” comments VelaDx CEO Michael Tillmann. “The new customized hardware and software on the Sentosa SX system will enhance workflow efficiency in laboratories and improve sample traceability.”

    The Sentosa SX101 works in combination with Qiagen’s Rotor-Gene Q real-time PCR system to automate extraction, PCR setup, amplification, and detection. Vela has already developed related supermagnetic bead-based nucleic acid extraction kits for use with the platform. The Sentosa SX Virus Total Nucleic Acid Kits is designed for purifying viral nucleic acids from nasal swabs. The Sentosa SX Bacteria gDNA Kits enable the purification of Gram-positive and Gram-negative bacteria genomic DNA from nasal swab and sputum samples.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?